Bristol-Myers Squibb
Shock for BMS as Opdivo misses goal in late-stage lung cancer trial
August 5, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo
Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016
July 29, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo
Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …
BMS names Fouad Namouni as new oncology development head
July 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo
Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Bristol-Myers Squibb settle $30 million California kickback lawsuit
July 20, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, california, lawsuit
Bristol-Myers Squibb (BMS) has agreed to pay $30 million to the California Department of Insurance to settle an almost decade …
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million
July 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant
Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …
Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation
UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …
Bristol-Myers Squibb’s Opdivo gets US FDA breakthrough therapy designation for advanced bladder cancer
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation
Bristol-Myers Squibb (NYSE:BMY) said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its immunotherapy Opdivo for the …
Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb
June 21, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, chief commercial officer
Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective …
Bristol-Myers Squibb presents Opdivo data at ASCO
June 6, 2016Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo
Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …
BMS says Phase III trials for Opdivo show improved overall survival in lung cancer
May 19, 2016Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo
Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …
Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma
May 18, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo
Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …
Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin
April 19, 2016Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial
New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer
April 19, 2016Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo
New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials
April 19, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous
Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo
Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
Latest content
